prasterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 795 53-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • intrarosa
  • 5,6-didehydroepiandrosterone
  • androstenolone
  • dehydroandrosterone
  • dehydroepiandrosterone
  • dehydroisoandrosterone
  • prasterone
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
  • Molecular weight: 288.43
  • Formula: C19H28O2
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -3.82
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6.50 mg V

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,BRAF,CDK5,EIF2AK3,ERBB2,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC 12
kinase-selectivity-class EIF2AK3,PDK2 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Butterfly rash 131.73 18.56 28 3867 2157 90622395
Periorbital oedema 100.14 18.56 28 3867 6771 90617781
Photosensitivity reaction 80.94 18.56 30 3865 17777 90606775
Head discomfort 72.33 18.56 27 3868 16306 90608246
Tinnitus 64.02 18.56 33 3862 43069 90581483
Off label use 62.43 18.56 142 3753 1102110 89522442
Swelling face 56.31 18.56 38 3857 81314 90543238
Application site discharge 47.82 18.56 8 3887 166 90624386
Feeling hot 43.65 18.56 32 3863 77976 90546576
Cellulitis 37.08 18.56 31 3864 91306 90533246
Therapeutic response unexpected 33.18 18.56 17 3878 21863 90602689
Headache 30.94 18.56 94 3801 862652 89761900
Vulvovaginal burning sensation 30.64 18.56 9 3886 2586 90621966
Hypothalamic pituitary adrenal axis suppression 30.16 18.56 6 3889 332 90624220
Dehydroepiandrosterone increased 27.17 18.56 3 3892 0 90624552
Granulomatous liver disease 23.99 18.56 6 3889 943 90623609
Gestational hypertension 20.96 18.56 7 3888 3055 90621497
Heart rate increased 20.89 18.56 25 3870 112877 90511675
Vaginal discharge 20.81 18.56 12 3883 19452 90605100
Extrasystoles 20.20 18.56 8 3887 5649 90618903
Eosinophilic oesophagitis 19.57 18.56 5 3890 856 90623696

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tendon calcification 52.57 26.86 7 767 71 42620490
Oestradiol increased 45.05 26.86 6 768 61 42620500
Progesterone increased 34.96 26.86 4 770 9 42620552
Aortic thrombosis 34.26 26.86 7 767 1063 42619498
Blood parathyroid hormone increased 30.16 26.86 7 767 1920 42618641

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Butterfly rash 140.51 19.56 28 3531 2103 110583637
Periorbital oedema 96.95 19.56 28 3531 10164 110575576
Head discomfort 75.98 19.56 27 3532 18973 110566767
Photosensitivity reaction 75.22 19.56 29 3530 25560 110560180
Tinnitus 71.11 19.56 36 3523 60504 110525236
Swelling face 51.98 19.56 34 3525 92287 110493453
Feeling hot 45.15 19.56 31 3528 91075 110494665
Cellulitis 44.63 19.56 35 3524 125981 110459759
Tendon calcification 41.96 19.56 7 3552 193 110585547
Headache 32.69 19.56 81 3478 882296 109703444
Aortic thrombosis 29.96 19.56 8 3551 2175 110583565
Off label use 27.74 19.56 108 3451 1500077 109085663
Application site discharge 24.93 19.56 5 3554 387 110585353
Dehydroepiandrosterone increased 24.74 19.56 3 3556 6 110585734
Oestradiol increased 23.95 19.56 4 3555 111 110585629
Granulomatous liver disease 22.67 19.56 6 3553 1578 110584162
Fatigue 21.16 19.56 86 3473 1215872 109369868
Blood parathyroid hormone increased 20.69 19.56 7 3552 4241 110581499

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A14AA07 ALIMENTARY TRACT AND METABOLISM
ANABOLIC AGENTS FOR SYSTEMIC USE
ANABOLIC STEROIDS
Androstan derivatives
ATC G03EA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Androgens and estrogens
ATC G03XX01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Other sex hormones and modulators of the genital system
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:50113 androgen
CHEBI has role CHEBI:50779 appetite enhancer
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:176497 geroprotector

Related Drugs by ATC class:

A14AA Androstan derivatives 8 drugs
androstanolonemetandienonemethenolonenorethandroloneoxandroloneoxymetholonequinbolonestanozolol
G03EA Androgens and estrogens 2 drugs
methyltestosteronetestosterone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Systemic lupus erythematosus indication 55464009 DOID:9074
Dyspareunia indication 71315007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
6.5MG INTRAROSA MILLICENT N208470 Nov. 16, 2016 RX INSERT VAGINAL 8957054 Jan. 8, 2030 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Sex hormone-binding globulin Secreted Kd 7.84 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.21 CHEMBL
Beta-glucuronidase Enzyme IC50 4.11 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.96 CHEMBL

External reference:

IDSource
4021360 VUID
N0000148779 NUI
D08409 KEGG_DRUG
2283-82-1 SECONDARY_CAS_RN
1927689 RXNORM
4021360 VANDF
4036745 VANDF
CHEBI:28689 CHEBI
AND PDB_CHEM_ID
CHEMBL90593 ChEMBL_ID
2869 INN_ID
DB01708 DRUGBANK_ID
459AG36T1B UNII
131731 MMSL
20676 MMSL
247058 MMSL
32118 MMSL
73034 MMSL
d04425 MMSL
004609 NDDF
413963008 SNOMEDCT_US
78316004 SNOMEDCT_US
C0011185 UMLSCUI
D003687 MESH_DESCRIPTOR_UI
5881 PUBCHEM_CID
2370 IUPHAR_LIGAND_ID
459AG36T1B INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 64011-601 INSERT 6.50 mg VAGINAL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-401 INSERT 6.50 mg VAGINAL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-501 INSERT 6.50 mg VAGINAL NDA 17 sections
Balance Plus Cream HUMAN OTC DRUG LABEL 4 82018-0028 CREAM 1000 mg TRANSDERMAL unapproved drug other 10 sections
Debaochun HUMAN OTC DRUG LABEL 7 82570-016 POWDER 10 g TOPICAL unapproved drug other 8 sections